 |
 |
|
|
RESÚMENES JUNIO 2008 |
Schizophrenia-Psychotic Disorders & Antipsychotics
(Haga un click en la información del journal
para acceder al resúmen)
5 – doble-ciego o
metanálisis; 4 – subanálisis o simple ciego; 3 –
revisión, abierto, básico; 2 – casos; 1 – opinión
GRATIS = Texto gratuito en algunos países de la región iberoamericana
(algunos artículos requieren ir a la tabla de contenidos del número actual de
la revista)
3! - Typical
and Atypical Antipsychotics - The Misleading Dichotomy. Results from the
Working Group 'Drugs in Psychiatry' (AGATE)
David Fischer-Barnicol, Stefan Lanquillon, Ekkehard Haen, Peter Zöfel, Horst J. Koch,
Matthias Dose, Helmfried E. Klein, Working Group
'Drugs in Psychiatry'
Neuropsychobiology 2008;57:80-87
5 - Topiramate add-on treatment in schizophrenia: a randomised, double-blind,
placebo-controlled clinical trial
H Afshar,
H Roohafza, G Mousavi, S Golchin,
Journal of Psychopharmacology 2008, First
published on May 30, 2008
3! - Clozapine: more than 900
mg/day may be needed
C MacCall, N Billcliff,
W Igbrude,
Journal of Psychopharmacology 2008, First
published on May 30, 2008
3 - Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal
activity and anxiolytic behaviour
L Dahan, H Husum, O Mnie-Filali, J Arnt, P Hertel, and N Haddjeri
Journal of Psychopharmacology 2008, First
published on May 30, 2008
5 - First-
v. second-generation antipsychotics and risk for diabetes in schizophrenia:
systematic review and meta-analysis
M. Smith, D. Hopkins, R. C. Peveler,
R. I. G. Holt, M. Woodward, K. Ismail
The
British Journal of Psychiatry (2008) 192: 406-411
3 -
Influence of 5-HT2C receptor and leptin
gene polymorphisms, smoking and drug treatment on metabolic disturbances in
patients with schizophrenia
Olga O. Yevtushenko, Stephen J. Cooper, Ryan O'Neill,
Jennifer K. Doherty, Jayne V. Woodside, Gavin P. Reynolds
The
British Journal of Psychiatry (2008) 192: 424-428
3 - Cycloid
Psychoses Revisited: Case Reports, Literature Review, and Commentary
Paola Salvatore;
Chaya Bhuvaneswar; Daniel Ebert; Carlo Maggini; Ross J.
Baldessarini
Harvard Review of
Psychiatry, Volume 16, Issue 3 May 2008, pages 167 - 180
3! - Prevention
of Negative Symptom Psychopathologies in First-Episode Schizophrenia
Two-Year Effects of
Reducing the Duration of Untreated Psychosis
Ingrid Melle, Tor K. Larsen, Ulrik Haahr, Svein Friis,
Jan O. Johannesen, Stein Opjordsmoen,
Bjørn R. Rund, Erik Simonsen, Per Vaglum, Thomas McGlashan
Arch Gen Psychiatry. 2008;65(6):634-640
3 -
Antipsychotic drug action: antagonism, inverse agonism
or partial agonism
Philip G. Strange
Trends in Pharmacological Sciences. Volume 29, Issue 6, June 2008, Pages 314-321
3< - Change in sexual dysfunction with aripiprazole:
a switching or add-on study
Amna Mir, Kuppuswami Shivakumar, Richard J
Williamson, Victoria McAllister, Veronica O'Keane, Katherine J Aitchison
Journal of Psychopharmacology, Vol. 22, No. 3, 244-253
(2008)
3< - Long-acting risperidone
improves negative symptoms in stable psychotic patients
VA Curtis, K Katsafouros, H-J Möller,
R Medori, E Sacchetti
Journal of Psychopharmacology, Vol. 22, No. 3, 254-261
(2008)
3< - Endogenous cannabinoids in
patients with schizophrenia and substance use disorder during quetiapine therapy
Stéphane Potvin, Édouard Kouassi, Olivier Lipp, Roch-Hugo Bouchard, Marc-André Roy, Marie-France Demers,
Alain Gendrons, Giuseppe Astarita,
Daniele Piomelli, Emmanuel Stip
Journal of Psychopharmacology, Vol. 22, No. 3, 262-269
(2008)
3 - Clinical consequences of switching antipsychotic
drugs in outpatients with schizophrenia: 36-month results from the European
Schizophrenia Outpatient Health Outcomes study
Novick, Diego; Haro, Josep Maria; Suarez, David;
Marques-Teixeira, Joao; Naber, Dieter
International
Clinical Psychopharmacology. 23(4):203-208, July 2008
4< - Paliperidone
extended-release tablets in schizophrenia patients previously treated with risperidone
Canuso, Carla M; Youssef,
Eriene A; Bossie, Cynthia
A; Turkoz, Ibrahim; Schreiner, Andreas; Simpson,
George M
International
Clinical Psychopharmacology. 23(4):209-215, July 2008
3 - Assessment of clinical and metabolic status, and
subjective well-being, in schizophrenic patients switched from typical and
atypical antipsychotics to ziprasidone
Rossi, Alessandro; Vita, Antonio; Tiradritti, Paola;
Romeo, Fabio
International Clinical Psychopharmacology.
23(4):216-222, July 2008
5< - A placebo-controlled
study of extract of ginkgo biloba added to clozapine in patients with treatment-resistant
schizophrenia
Doruk, Ali; Uzun,
Ozcan; Ozsahin, Aytekin
International
Clinical Psychopharmacology. 23(4):223-227, July 2008
3! - Suicide attempts of schizophrenia patients: A
case-controlled study in tertiary care
Yoram Barak, Yehuda Baruch, Anat
Achiron and Dov
Aizenberg
Journal of Psychiatric Research. Volume 42, Issue 10, August 2008, Pages 822-826
3 - Antipsychotic-Induced Weight Gain in Chronic and
First-Episode Psychotic Disorders: A Systematic Critical Reappraisal
Alvarez-Jimenez, Mario; Gonzalez-Blanch, Cesar; Crespo-Facorro,
Benedicto; Hetrick, Sarah;
Rodriguez-Sanchez, Jose Manuel; Perez-Iglesias, Rocio;
Vazquez-Barquero, Jose Luis
CNS Drugs. 22(7):547-562, 2008
3 - Smoking
and schizophrenia: Epidemiological and clinical features
L'Encéphale.
Volume 34, Issue 3, June 2008, Pages 299-305
3 - Long-term treatment with flupentixol
results of a post-marketing surveillance study
T. Messer, T. Glaser, H. Landen, and
M. Schmauss
Journal of Psychopharmacology On
Line First. Jun 2008
3! - The role of dopamine D3, 5-HT2A
and 5-HT2C receptor variants as pharmacogenetic determinants in
tardive dyskinesia in African-Caribbean patients under chronic antipsychotic
treatment
B. Wilffert, A. F. Y. Al Hadithy, V.
J. Sing, G. Matroos, H. W. Hoek, J. van Os, R. Bruggeman, J. R. B. J. Brouwers,
and P. N. van Harten
Journal of Psychopharmacology On
Line First. Jun 2008
3 - Amisulpride doses and
plasma levels in different age groups of patients with schizophrenia or
schizoaffective disorder
M. J. Müller, F. X. Eich, B.
Regenbogen, J. Sachse, S. Härtter, and C. Hiemke
Journal of Psychopharmacology First
published on June 18, 2008
3 - Cardiovascular variability during treatment with
haloperidol, olanzapine or risperidone
in recent-onset schizophrenia
R. J. Hempel, J. H. M. Tulen, N. J. M.
van Beveren, C. H. Röder, and M. W. Hengeveld
Journal of Psychopharmacology First
published on June 18, 2008
4< - Efficacy and tolerability of ziprasidone
versus risperidone as augmentation in patients partially
responsive to clozapine: a randomised controlled
clinical trial
M. Zink, A. Kuwilsky,
B. Krumm, and H. Dressing
Journal of
Psychopharmacology First published on June 18, 2008
3 - Effectiveness
of risperidone long-acting injection in first-episode
schizophrenia: In naturalistic setting
Borah Kim, Sang-Hyuk Lee, Tae Kyou Choi, ShinYoung Suh, Yong Woo Kim, EunHee Lee and Ki Hwan Yook
3! -
Predictors of the course of illness in outpatients with schizophrenia: A
prospective three year study
J.M. Haro, D. Novick, D. Suarez, S. Ochoa and M. Roca
4! -
Predicting response to atypical antipsychotics based on early response in the
treatment of schizophrenia
Bruce J. Kinon, Lei Chen, Haya Ascher-Svanum, Virginia L. Stauffer, Sara Kollack-Walker, Jennifer L. Sniadecki and John M. Kane
Schizophrenia Research. Volume 102, Issues 1-3,
July 2008, Pages 230-240
5< - Early
onset of antipsychotic response in the treatment of acutely agitated patients
with psychotic disorders
Ofer Agid
, Shitij Kapur, Lewis Warrington, Antony Loebel and Cynthia Siu
Schizophrenia Research. Volume 102, Issues 1-3,
July 2008, Pages 241-248
3! - Breast
cancer in women suffering from serious mental illness
Yoram Barak, Tali
Levy, Anat Achiron and Dov Aizenberg
Schizophrenia Research. Volume 102, Issues 1-3,
July 2008, Pages 249-253
3! - Are
metabolic indices different between drug-naïve first-episode psychosis patients
and healthy controls?
Sarojini Sengupta, Maria A. Parrilla-Escobar, Ruby Klink, Ferid Fathalli, Ying Kin Ng, Emmanuel Stip, Trino Baptista, Ashok Malla and Ridha Joober
Schizophrenia Research. Volume 102, Issues 1-3, July 2008, Pages 329-336
3 - Less Is
More: Antipsychotic Drug Effects Are Greater with Transient Rather Than
Continuous Delivery
Anne-Noël Samaha, Greg E. Reckless, Philip Seeman,
Mustansir Diwan, José N. Nobrega and Shitij Kapur
Biological Psychiatry. Volume 64, Issue 2, 15
July 2008, Pages 145-152
3! - Tardive Dyskinesia and the 3-Year
Course of Schizophrenia: Results From a Large, Prospective, Naturalistic Study
Haya Ascher-Svanum, Baojin Zhu,
Douglas Faries, Xiaomei Peng, Bruce J. Kinon, and
Mauricio Tohen
J Clin Psychiatry
June 24, 2008: e1-e9
5 - Olanzapine orally disintegrating tablet vs. risperidone
oral solution in the treatment of acutely agitated psychotic patients
Kotaro Hatta, Toshitaka
Kawabata, Kenichi Yoshida, Hiroshi Hamakawa, Toru Wakejima, Ko Furuta,
Mitsuru Nakamura, Toyoaki Hirata, Chie Usui, Hiroyuki
Nakamura and Yutaka Sawa
General Hospital Psychiatry. Volume 30, Issue 4,
July-August 2008, Pages 367-371
3 - Depot and oral antipsychotics: patient preferences
and attitudes are not the same thing
M X Patel, N De Zoysa, M Bernadt, and A David
Journal of Psychopharmacology First
published on June 26, 2008
3 - Remission in schizophrenia: the relationship to
baseline symptoms and changes in symptom domains during a one-year study
D L Kelly,
Journal of Psychopharmacology First
published on June 26, 2008
3 - Switching schizophrenia patients from typical neuroleptics to olanzapine:
Effects on BOLD response during attention and working memory
Florian Schlagenhauf, Torsten
Wüstenberg, Katharina Schmack,
Martin Dinges, Jana Wrase,
Michael Koslowski, Thorsten Kienast,
Michael Bauer, Jürgen Gallinat,
Georg Juckel and Andreas Heinz
European Neuropsychopharmacology. Volume 18, Issue 8, August 2008, Pages 589-599
3 - Neurocognitive Allied Phenotypes for Schizophrenia and
Bipolar Disorder
S. Kristian Hill, Margret S. H.
Harris, Ellen S. Herbener, Mani Pavuluri
and John A. Sweeney
Schizophrenia
Bulletin 2008 34(4):743-759
3 -
Structural Cerebral Variations as Useful Endophenotypes
in Schizophrenia: Do They Help Construct "Extended Endophenotypes"?
Konasale
M. Prasad and Matcheri S. Keshavan
Schizophrenia
Bulletin 2008 34(4):774-790
3!
- Comparison of Intranasal
Administration of Haloperidol with Intravenous and Intramuscular
Administration: A Pilot Pharmacokinetic Study
Pharmacotherapy 2008; Volume:
28 | Issue: 7: 875-882
3 - Effects
of Age and Age of Onset on Prescribed Antipsychotic Dose in Schizophrenia Spectrum
Disorders: A Survey of 1,418 Patients in
Hiroyuki Uchida, Takefumi Suzuki,
M.D., David C. Mamo, Benoit H. Mulsant,
Akira Tanabe, Ataru Inagaki, Koichiro
Watanabe, Gohei Yagi, and
Masayuki Tomita
Am J Geriatr Psychiatry
16:584-593, July 2008
GRATIS 3 - Abilify (aripiprazole) Tablets and Oral Solution, Discmelt Orally Disintegrating Tablets, Injection for
Intramuscular Use Only
Summary View: Safety Labeling
Changes - February 2008
3 - Quetiapine facilitates oligodendrocyte
development and prevents mice from myelin breakdown and behavioral
changes
L Xiao, H Xu, Y Zhang, Z Wei, J He, W Jiang,
X Li, L E Dyck, R M Devon, Y Deng
and X M Li
Molecular
Psychiatry (2008) 13, 697–708
3 - Erythropoietin
Prevents Haloperidol Treatment-Induced Neuronal Apoptosis through Regulation of
BDNF
Anilkumar Pillai, Krishnan M Dhandapani,
Bindu A Pillai, Alvin
V Terry Jr and Sahebarao
P Mahadik
Neuropsychopharmacology (2008) 33, 1942–1951
GRATIS 3 - Cannabis
use and the risk of developing a psychotic disorder
WAYNE HALL and
LOUISA DEGENHARDT
World Psychiatry. 2008 June;
7(2): 68–71
| Regresar a RESÚMENES JUNIO 2008 |
